A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 542 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Investing in volunteers since 2002: The tale of time July 11, 2022 EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) June 1, 2023 Re-Thinking Community December 10, 2021 GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... January 5, 2022 Load more HOT NEWS Mediterranean Diet Associated with a Higher Probability of Response in Patients... FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma Improving research with registered reports Tips On Staying Cool During a Heat Wave
